Black Rose Industries LtdQ4 FY21

Black Rose Industries Ltd Q4 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: 107P/E: 19.2Market Cap: ₹552 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Black Rose Industries aims to achieve peak revenues of Rs.150 Crores from Acrylamide (20,000 tons capacity) and Rs.100 Crores from PAM liquid (40,000 tons capacity), based on current pricing.
  • The company targets revenue of Rs.650 Crores by FY2023, comprising Rs.150 Crores from Acrylamide, Rs.100 Crores from PAM liquid, Rs.200 Crores from PAM solids, and Rs.200 Crores from distribution.
  • Acrylamide capacity utilization was 100% in Q3 FY2021, with a focus on increasing export volumes, especially to the US market.
  • PAM liquid is focused on ceramic binder applications with utilization around 25%; potential exists in textile, paper, and other segments.
  • Polyacrylamide solids project is still under R&D and will proceed once technical issues are resolved.
  • New products like N-Methylol Acrylamide (NMA) with 2000 tons capacity target Rs.30-50 Crores revenue and import substitution opportunities.
  • Expansion plans depend on achieving 80-90% capacity utilization; company will explore new chemical space opportunities over 3-5 years.

See what Black Rose Industries Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • As of the May 31, 2021 earnings call, Black Rose Industries Limited did not have any immediate plans for capital raising.
  • The management indicated they would consider raising capital only when the need arises.
  • Several projects and discussions related to potential capital raising are ongoing at the board and senior management levels.
  • Any announcements about fundraising through debt or equity will be communicated to investors in due course.
  • No specific timelines or amounts for future fundraising were disclosed during the call.

See what Black Rose Industries Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Rs. 8 Crores capex planned for manufacturing Acrylamide powder (3600 tons capacity) at existing Jhagadia plant; expected revenue potential ~Rs. 65 Crores.
  • Additional capex expected for N-Methylol Acrylamide (NMA) product which is currently in lab and piloting stages; exact figures to be determined post-piloting.
  • Polyacrylamide solid plant (10000 tons capacity) under implementation; no clear timeline but R&D and piloting ongoing.
  • Future capital raises will be considered as per project requirements; no current announcements on new capital raising.
  • Expansion plans include scaling existing product lines when utilization nears 80-90%, with potential new chemical projects being evaluated.
  • Strategy prioritizes faster commercialization products like NMA and Acrylamide solids over polyacrylamide solid due to lower gestation period and existing client demand.

Track Black Rose Industries Ltd — get its next earnings analysis in your feed

Margin guidance

Category 3
  • Black Rose Industries aims to achieve peak revenues of approximately Rs. 650 Crores by FY2023, comprising Rs.150 Crores from Acrylamide, Rs.100 Crores from PAM liquid, Rs.200 Crores from PAM solids, and Rs.200 Crores from distribution.
  • Capacity utilization improvements, particularly from export growth, are expected to boost revenues, with Acrylamide expanded to 20,000 tons and PAM liquid at 40,000 tons capacity.
  • Margins are currently sustainable but subject to raw material price fluctuations and COVID-19 impacts; efforts to improve operational efficiencies are ongoing.
  • New products like N-Methylol Acrylamide (NMA) and Acrylamide solids are prioritized for quicker market capture and additional earnings.
  • The company expects to maintain or improve EBITDA margins, with profitability scaling alongside volume increases, higher realizations, and cost savings.
  • Continuous quarterly and annual disclosures will keep investors updated on performance and growth trajectory.

Order book

  • The transcript does not explicitly mention the current or expected order book or pending orders by exact figures.
  • However, it was stated that in Q3, the company operated at close to 100% of its expanded merchant sales capacity of 20,000 metric tons due to very large orders in that particular month.
  • Exports, particularly to the US market, have started to pick up again after previous slowdowns caused by factors like oil price crashes and increased logistics costs.
  • The company is focusing on increasing export volumes for Acrylamide to boost capacity utilization in FY2022.
  • Large orders and improved export demand indicate a strong order book momentum but no specific quantitative details on pending orders were given.
  • The company remains cautious about market uncertainties caused by COVID-19 variants and lockdowns which could impact order flows.

How does Black Rose Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisBlack Rose Industries Ltd
Rev 3Mar 3

How does Black Rose Industries Ltd rank in Chemicals & Petrochemicals?

Compare Black Rose Industries Ltd against every Chemicals & Petrochemicals company (Q4 FY21) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Sudarshan Chemical Industries Ltd (Q1 FY27)

    The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…

  • Indo Borax & Ch. (Q1 FY27)

    250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…

  • SRF Ltd (Q1 FY27)

    Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…

  • Deepak Fertilis. (Q1 FY27)

    Long-term demand-supply balance looks stable with 6-7% market growth, supporting sustained revenues despite new capacity additions. Key concall takeaways from…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →